LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.

    Simon, David / Tascilar, Koray / Krönke, Gerhard / Kleyer, Arnd / Zaiss, Mario M / Heppt, Franz / Meder, Christine / Atreya, Raja / Klenske, Entcho / Dietrich, Peter / Abdullah, Abdullah / Kliem, Thorsten / Corte, Giulia / Morf, Harriet / Leppkes, Moritz / Kremer, Andreas E / Ramming, Andreas / Pachowsky, Milena / Schuch, Florian /
    Ronneberger, Monika / Kleinert, Stefan / Maier, Clara / Hueber, Axel J / Manger, Karin / Manger, Bernhard / Berking, Carola / Tenbusch, Matthias / Überla, Klaus / Sticherling, Michael / Neurath, Markus F / Schett, Georg

    Nature communications

    2020  Volume 11, Issue 1, Page(s) 3774

    Abstract: ... incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared ... Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. ... Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated ...

    Abstract Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.
    MeSH term(s) Adult ; Antibodies, Viral/blood ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/immunology ; Cytokines/antagonists & inhibitors ; Female ; Humans ; Immune System Diseases/drug therapy ; Immunoglobulin G/blood ; Immunosuppressive Agents/administration & dosage ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/immunology ; Prevalence ; Risk ; Seroconversion
    Chemical Substances Antibodies, Viral ; Cytokines ; Immunoglobulin G ; Immunosuppressive Agents
    Keywords covid19
    Language English
    Publishing date 2020-07-24
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-020-17703-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

    Simon, David / Tascilar, Koray / Krönke, Gerhard / Kleyer, Arnd / Zaiss, Mario M / Heppt, Franz / Meder, Christine / Atreya, Raja / Klenske, Entcho / Dietrich, Peter / Abdullah, Abdullah / Kliem, Thorsten / Corte, Giulia / Morf, Harriet / Leppkes, Moritz / Kremer, Andreas E / Ramming, Andreas / Pachowsky, Milena / Schuch, Florian /
    Ronneberger, Monika / Kleinert, Stefan / Maier, Clara / Hueber, Axel J / Manger, Karin / Manger, Bernhard / Berking, Carola / Tenbusch, Matthias / Überla, Klaus / Sticherling, Michael / Neurath, Markus F / Schett, Georg

    Nat Commun

    Abstract: ... incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared ... Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection. ... Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated ...

    Abstract Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #672188
    Database COVID19

    Kategorien

  3. Article ; Online: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

    David Simon / Koray Tascilar / Gerhard Krönke / Arnd Kleyer / Mario M. Zaiss / Franz Heppt / Christine Meder / Raja Atreya / Entcho Klenske / Peter Dietrich / Abdullah Abdullah / Thorsten Kliem / Giulia Corte / Harriet Morf / Moritz Leppkes / Andreas E. Kremer / Andreas Ramming / Milena Pachowsky / Florian Schuch /
    Monika Ronneberger / Stefan Kleinert / Clara Maier / Axel J. Hueber / Karin Manger / Bernhard Manger / Carola Berking / Matthias Tenbusch / Klaus Überla / Michael Sticherling / Markus F. Neurath / Georg Schett

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 7

    Abstract: ... a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory ... diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are ... Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show ...

    Abstract Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.
    Keywords Science ; Q ; covid19
    Language English
    Publishing date 2020-07-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

    David Simon / Koray Tascilar / Gerhard Krönke / Arnd Kleyer / Mario M. Zaiss / Franz Heppt / Christine Meder / Raja Atreya / Entcho Klenske / Peter Dietrich / Abdullah Abdullah / Thorsten Kliem / Giulia Corte / Harriet Morf / Moritz Leppkes / Andreas E. Kremer / Andreas Ramming / Milena Pachowsky / Florian Schuch /
    Monika Ronneberger / Stefan Kleinert / Clara Maier / Axel J. Hueber / Karin Manger / Bernhard Manger / Carola Berking / Matthias Tenbusch / Klaus Überla / Michael Sticherling / Markus F. Neurath / Georg Schett

    Nature Communications, Vol 11, Iss 1, Pp 1-

    2020  Volume 7

    Abstract: ... a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory ... diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are ... Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show ...

    Abstract Cytokine storm seems to be a common feature of severe COVID-19 pathology. Here, the authors show a reduced rate of SARS-CoV2 positivity in a large population of patients with immune-mediated inflammatory diseases if they are already being treated with cytokine or JAK inhibitors, indicating these treatments are safe to continue and are possibly protective against COVID19.
    Keywords Science ; Q
    Language English
    Publishing date 2020-07-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

    Simon, David / Tascilar, Koray / Krönke, Gerhard / Kleyer, Arnd / Zaiss, Mario M. / Heppt, Franz / Meder, Christine / Atreya, Raja / Klenske, Entcho / Dietrich, Peter / Abdullah, Abdullah / Kliem, Thorsten / Corte, Giulia / Morf, Harriet / Leppkes, Moritz / Kremer, Andreas E. / Ramming, Andreas / Pachowsky, Milena / Schuch, Florian /
    Ronneberger, Monika / Kleinert, Stefan / Maier, Clara / Hueber, Axel J. / Manger, Karin / Manger, Bernhard / Berking, Carola / Tenbusch, Matthias / Überla, Klaus / Sticherling, Michael / Neurath, Markus F. / Schett, Georg

    Nature Communications

    2020  Volume 11, Issue 1

    Keywords General Biochemistry, Genetics and Molecular Biology ; General Physics and Astronomy ; General Chemistry ; covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2553671-0
    ISSN 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-020-17703-6
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Book ; Online: Faculty Opinions recommendation of Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.

    Satsangi, Jack

    Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

    2020  

    Keywords covid19
    Publisher Faculty Opinions Ltd
    Publishing country uk
    Document type Book ; Online
    DOI 10.3410/f.738374557.793577971
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Book ; Online: ekoraytascilar/naturecommunicationscovid

    ekoraytascilar

    Data and analysis code to accompany "Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion"

    2020  

    Abstract: ... with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 ... This release contains raw datasets and analysis code for the research paper titled "Patients ... seroconversion" ...

    Abstract This release contains raw datasets and analysis code for the research paper titled "Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion"
    Keywords covid19
    Publishing date 2020-07-03
    Publishing country eu
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top